Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
09 août 2023 08h05 HE
|
Palisade Bio, Inc.
– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 ...
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
08 août 2023 08h00 HE
|
Cocrystal Pharma, Inc.
First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against noroviruses including GII.4 pandemic strains ...
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
03 août 2023 13h25 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
Aridis Pharmaceuticals Announces $2 Million Offering
02 août 2023 08h17 HE
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
26 juil. 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
12 juil. 2023 08h00 HE
|
Aridis Pharmaceuticals, Inc.
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company...
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
05 juil. 2023 08h45 HE
|
Palisade Bio, Inc.
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
05 juil. 2023 08h33 HE
|
The Greater Cannabis Company, Inc.
BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next...
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
20 juin 2023 08h00 HE
|
Aridis Pharmaceuticals, Inc.
LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical...
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
20 juin 2023 08h00 HE
|
Timber Pharmaceuticals
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for...